Candesartan
Candesartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for ATACAND tablets (candesartan cilexetil), lists two uses: treating high blood pressure in adults and in children 1 to under 17 years of age, and treating heart failure (NYHA class II-IV), where the label says it reduces cardiovascular death and heart failure hospitalization. Atacand is the brand name on the label read.
Also called Atacand · Candesartan cilexetil
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 214354; UNII R85M2X0D68. The label names the substance as candesartan cilexetil, a prodrug that the label says is hydrolyzed to candesartan, so UNII R85M2X0D68 is the UNII of the cilexetil ester and is a broad match. MeSH has no descriptor for candesartan; C077793 is the MeSH supplementary concept record for candesartan cilexetil, also a broad match. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the ANI Pharmaceuticals, Inc. label for ATACAND (candesartan cilexetil) tablets, application NDA020838, effective 2025-12-22 in openFDA; Drugs@FDA lists the application's sponsor as ANI PHARMS. Generic candesartan labels and the ATACAND HCT combination label were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 8 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 8
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 0 | 3 | 0 | 3 |
| Phase 3 | 1 | 1 | 0 | 2 |
| Phase 4 | 0 | 2 | 1 | 3 |
| All phases | 1 | 6 | 1 | 8 |
Conditions these trials study
- Hypertension (high blood pressure)
- Cardiomyopathy (heart muscle disease)
- Dilated cardiomyopathy
- Dyslipidemia
- Heart failure
- Type 2 diabetes
Sponsors with the most trials
- Boryung Pharmaceutical Co., Ltd
- Cristina Avendaño Solá
- Emory University
- HK inno.N Corporation
- Takeda
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
R85M2X0D68 -
C077793
Claims and evidence
Context Children for whom the US label of candesartan (Atacand) lists hypertension as an indication: children 1 to under 17 years of age
- Recipient
- Child
- Population
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Label wording: children 1 to under 17 years of age
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Children with hypertension (children 1 to under 17 years of age)
- Excluded
- None stated
The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children 1 to under 17 years of age.
Applies to Child Children for whom the US label of candesartan (Atacand) lists hypertension as an indication: children 1 to under 17 years of age
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-12-22
- Source state
- Current
- Version fingerprint
6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251222.
- Retrieved
- Source effective date
- 2025-12-22
- Source state
- Current
- Version fingerprint
6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients for whom the US label of candesartan (Atacand) lists an indication: adult hypertension, NYHA class II-IV heart failure
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children 1 to under 17 years of age); the heart failure indication does not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults for hypertension, as the passage read states; not stated for heart failure
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adult patients with hypertension
- Patients with heart failure (NYHA class II-IV)
- Excluded
- None stated
The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children 1 to under 17 years of age, recorded separately); and for the treatment of heart failure (NYHA class II-IV), with the label stating that the medicine reduces cardiovascular death and heart failure hospitalization.
Applies to Recipient not specified Patients for whom the US label of candesartan (Atacand) lists an indication: adult hypertension, NYHA class II-IV heart failure
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-12-22
- Source state
- Current
- Version fingerprint
6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251222.
- Retrieved
- Source effective date
- 2025-12-22
- Source state
- Current
- Version fingerprint
6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application NDA020838, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ec1683f25cf3821591331aea65021120395a52d28829ac5fc903c50d651cbef8- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children 1 to under 17 years of age.
Applies to Child Children for whom the US label of candesartan (Atacand) lists hypertension as an indication: children 1 to under 17 years of age
Population, setting and follow-up
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Label wording: children 1 to under 17 years of age
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-12-22
- Source state
- Current
- Version fingerprint
6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251222.
- Retrieved
- Source effective date
- 2025-12-22
- Source state
- Current
- Version fingerprint
6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
ATACAND
No label from the application holder was found in the openFDA label dataset for application NDA020838. This page does not show another labeler's label in its place.
ATACAND HCT
No label from the application holder was found in the openFDA label dataset for application NDA021093. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Patients for whom the US label of candesartan (Atacand) lists an indication: adult hypertension, NYHA class II-IV heart failure
The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children 1 to under 17 years of age, recorded separately); and for the treatment of heart failure (NYHA class II-IV), with the label stating that the medicine reduces cardiovascular death and heart failure hospitalization.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists NYHA class II to IV heart failure as an indication: Heart failure
Applies to Recipient not specified Patients for whom the US label of candesartan (Atacand) lists an indication: adult hypertension, NYHA class II-IV heart failure
The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children 1 to under 17 years of age, recorded separately); and for the treatment of heart failure (NYHA class II-IV), with the label stating that the medicine reduces cardiovascular death and heart failure hospitalization.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 2
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 8
Record details
- Record id
cardio:candesartan- Content hash
2731a12b2f9c4c04b600b2872d010a8589c82f9aeffb9935a0b52ba638fba0a2